1. Home
  2. VABK vs URGN Comparison

VABK vs URGN Comparison

Compare VABK & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VABK
  • URGN
  • Stock Information
  • Founded
  • VABK 1998
  • URGN 2004
  • Country
  • VABK United States
  • URGN United States
  • Employees
  • VABK N/A
  • URGN N/A
  • Industry
  • VABK Major Banks
  • URGN Biotechnology: Pharmaceutical Preparations
  • Sector
  • VABK Finance
  • URGN Health Care
  • Exchange
  • VABK Nasdaq
  • URGN Nasdaq
  • Market Cap
  • VABK 205.9M
  • URGN 181.2M
  • IPO Year
  • VABK N/A
  • URGN 2017
  • Fundamental
  • Price
  • VABK $36.60
  • URGN $14.82
  • Analyst Decision
  • VABK
  • URGN Strong Buy
  • Analyst Count
  • VABK 0
  • URGN 9
  • Target Price
  • VABK N/A
  • URGN $26.81
  • AVG Volume (30 Days)
  • VABK 3.9K
  • URGN 5.9M
  • Earning Date
  • VABK 07-18-2025
  • URGN 08-12-2025
  • Dividend Yield
  • VABK 3.93%
  • URGN N/A
  • EPS Growth
  • VABK 3.77
  • URGN N/A
  • EPS
  • VABK 3.30
  • URGN N/A
  • Revenue
  • VABK $54,953,000.00
  • URGN $91,871,000.00
  • Revenue This Year
  • VABK N/A
  • URGN $36.65
  • Revenue Next Year
  • VABK N/A
  • URGN $88.35
  • P/E Ratio
  • VABK $11.09
  • URGN N/A
  • Revenue Growth
  • VABK 1.60
  • URGN 8.98
  • 52 Week Low
  • VABK $29.80
  • URGN $3.42
  • 52 Week High
  • VABK $44.00
  • URGN $18.15
  • Technical
  • Relative Strength Index (RSI)
  • VABK 53.24
  • URGN 73.80
  • Support Level
  • VABK $36.48
  • URGN $6.92
  • Resistance Level
  • VABK $36.91
  • URGN $15.22
  • Average True Range (ATR)
  • VABK 0.30
  • URGN 1.57
  • MACD
  • VABK -0.02
  • URGN 1.17
  • Stochastic Oscillator
  • VABK 62.20
  • URGN 96.49

About VABK Virginia National Bankshares Corporation

Virginia National Bankshares Corp is a bank holding company which is engaged in the commercial and retail banking business. The bank offers a range of banking and related financial services, including checking accounts, negotiable order of withdrawal accounts, money market deposit accounts, certificates of deposit, individual retirement accounts and other depository services. Its segments include the Bank, VNB Trust and Estate Services, Sturman Wealth Advisors, and Masonry Capital. The Bank's commercial banking activities involve making loans, taking deposits and offering related services to individuals, businesses, and charitable organizations.

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

Share on Social Networks: